Recruiting
Phase 2 / Phase 3
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
About this study
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
- Condition
- Primary Central Nervous System Lymphoma
- Tested
- R-IDARAM plus intrathecal chemotherapy
- Sponsor
- Navy General Hospital, Beijing
Who can join
- Age
- 18 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Minimum age: 18 years
- Maximum age: 75 years
- Study condition: Primary Central Nervous System Lymphoma
- Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).
Exclusion 10
- Involved sites other than the brain, meninges, CSF, or the eyes.
- Age less than 18 years or greater than 75 years.
- Inadequate bone marrow capacity (defined as neutrophils\<1.5 ×10\^9/L, platelets \<100 ×10\^9/L, and hemoglobin level\< 8 g/dL).
- Known cause of immunosuppression (ie, HIV type I infection).
- Any previous malignancy.
- Creatinine clearance below 60 mL/min.
- Heart insufficiency (NYHA IIIB or IV).
- Uncontrolled infection.
- Noncompensated active pulmonary or liver disease.
- Previously treated for PCNSL, except by corticosteroids.
Where
1 site, 1 recruiting
Navy General Hospital
Beijing, Beijing Municipality, China
Contact
-
Liren Qian, M.D.
+861066957676 qlr2007@126.com
Potential match only. Final eligibility is determined by the study team.